You are here: Industry Insights > Synthorx

News List

Sanofi announces it will acquire Synthorx for $2.5 billion europeanpharmaceuticalreview
December 16, 2019
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline pharmaceutical-business-review
December 12, 2019
Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.
Sanofi agrees to pay $2.5bn for biotech firm Synthorx pharmaceutical-technology
December 10, 2019
French pharmaceutical company Sanofi has agreed to acquire all outstanding shares of biotechnology firm Synthorx for a total consideration of $2.5bn, or $68 per share in cash.
Preclinical biotech Synthorx wants a $100M IPO fiercebiotech
November 15, 2018
Moderna will be getting all the headlines for its monster $500 million IPO attempt this week, but that shouldn’t overshadow the major $100 million IPO that early-stage Synthorx has just announced, and what this says about the biotech market.
Synthorx reels in $63M to push synthetic cytokines into the clinic pharmafile
May 02, 2018
Synthorx raised a $63 million series C that will advance its pipelines of synthetic cytokines, which are designed to improve the efficacy ...